Vaxart oral vaccine platform cites strong safety, 2027 milestones
The company says its oral vaccine platform is advancing through late-stage trials across COVID-19, norovirus and flu, supported by safety and immune-response data, plus partnerships and government funding, with major milestones expected in 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.